Drug Delivery Systems for the Oral Administration of Antimicrobial Peptides: Promising Tools to Treat Infectious Diseases

被引:34
作者
Deshayes, Caroline [1 ]
Arafath, Md. Nasir [2 ]
Apaire-Marchais, Veronique [1 ]
Roger, Emilie [2 ]
机构
[1] Univ Angers, INRAE, SIFCIR, SFR QUASAV, Angers, France
[2] Univ Angers, INSERM, CNRS, MINT,SFR ICAT, Angers, France
来源
FRONTIERS IN MEDICAL TECHNOLOGY | 2022年 / 3卷
关键词
oral route; antimicrobial peptides (AMPs); infectiology; pharmaceutical forms; drug delivery systems (DDS); LIPOSOME-ENCAPSULATED NISIN; IN-VITRO CHARACTERIZATION; ALGINATE MICROPARTICLES; VANCOMYCIN; BIOAVAILABILITY; NANOPARTICLES; RESISTANCE; EFFICACY; LFF571; FORMULATION;
D O I
10.3389/fmedt.2021.778645
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Antimicrobial peptides (AMPs) have a great potential to face the global expansion of antimicrobial resistance (AMR) associated to the development of multidrug-resistant (MDR) pathogens. AMPs are usually composed of 10-50 amino acids with a broad structural diversity and present a range of antimicrobial activities. Unfortunately, even if the oral route is the most convenient one, currently approved therapeutic AMPs are mostly administrated by the intravenous route. Thus, the development of novel drug delivery systems (DDSs) represents a promising opportunity to protect AMPs from chemical and enzymatic degradation through the gastrointestinal tract and to increase intestinal permeability leading to high bioavailability. In this review, the classification and properties as well as mechanisms of the AMPs used in infectiology are first described. Then, the different pharmaceutical forms existing in the market for oral administration are presented. Finally, the formulation technologies, including microparticle- and nanoparticle-based DDSs, used to improve the oral bioavailability of AMPs are reviewed.
引用
收藏
页数:13
相关论文
共 101 条
  • [21] Ex-vivo evaluation of alginate microparticles for Polymyxin B oral administration
    Coppi, Gilberto
    Sala, Nicoletta
    Bondi, Moreno
    Sergi, Santo
    Iannuccelli, Valentina
    [J]. JOURNAL OF DRUG TARGETING, 2006, 14 (09) : 599 - 606
  • [22] Antimicrobial Resistance: Implications and Costs
    Dadgostar, Porooshat
    [J]. INFECTION AND DRUG RESISTANCE, 2019, 12 : 3903 - 3910
  • [23] Antimicrobial Peptides: a New Frontier in Antifungal Therapy
    De Cesare, Giuseppe Buda
    Cristy, Shane A.
    Garsin, Danielle A.
    Lorenz, Michael C.
    [J]. MBIO, 2020, 11 (06): : 1 - 21
  • [24] Antimicrobial and Antibiofilm Peptides
    Di Somma, Angela
    Moretta, Antonio
    Cane, Carolina
    Cirillo, Arianna
    Duilio, Angela
    [J]. BIOMOLECULES, 2020, 10 (04)
  • [25] Clinical Applications of Antimicrobial Peptides (AMPs): Where do We Stand Now?
    Divyashree, Mithoor
    Mani, Madhu K.
    Reddy, Dhanasekhar
    Kumavath, Ranjith
    Ghosh, Preetam
    Azevedo, Vasco
    Barh, Debmalya
    [J]. PROTEIN AND PEPTIDE LETTERS, 2020, 27 (02) : 120 - 134
  • [26] Advances in oral peptide therapeutics
    Drucker, Daniel J.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (04) : 277 - 289
  • [27] European Medicines Agency E, 2021, DAT SUBM AUTH MED
  • [28] European Medicines Agency (EMA), 2001, ANN 3 AM REL SECT SU, P45
  • [29] FDA, Summary of product characteristics, labelling and package leaflet
  • [30] Fleming A, 1922, BRIT J EXP PATHOL, V3, P252